F
Frederik Damm
Researcher at Humboldt University of Berlin
Publications - 76
Citations - 4353
Frederik Damm is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Mutation & Leukemia. The author has an hindex of 30, co-authored 70 publications receiving 3717 citations. Previous affiliations of Frederik Damm include Hannover Medical School & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Felicitas Thol,Frederik Damm,Andrea Ludeking,Claudia Winschel,Katharina Wagner,Michael A. Morgan,Haiyang Yun,Gudrun Göhring,Brigitte Schlegelberger,Dieter Hoelzer,Michael Lübbert,Lothar Kanz,Walter Fiedler,Hartmut Kirchner,Gerhard Heil,Jürgen Krauter,Arnold Ganser,Michael Heuser +17 more
TL;DR: DNMT3A mutations are frequent in younger patients with AML and are associated with an unfavorable prognosis, which has an unfavorable effect on OS, RFS, and CR rate in NPM1/FLT3-ITD high-risk but not in low-risk patients.
Journal ArticleDOI
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen,Lars Bullinger,Andrea Corbacioglu,Mathijs A. Sanders,Claudia Erpelinck,Bas J. Wouters,Sonja C P A M van der Poel-van de Luytgaarde,Frederik Damm,Jürgen Krauter,Arnold Ganser,Richard F. Schlenk,Bob Löwenberg,Ruud Delwel,Hartmut Döhner,Peter J. M. Valk,Konstanze Döhner +15 more
TL;DR: It is proposed that CEBPA(dm) should be clearly defined from CEbPA(sm) AML and considered as a separate entity in the classification of AML.
Journal ArticleDOI
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Felicitas Thol,Inna Friesen,Frederik Damm,Haiyang Yun,Eva M. Weissinger,Jürgen Krauter,Katharina Wagner,Anuhar Chaturvedi,Amit Sharma,Martin Wichmann,Gudrun Göhring,Christiane Schumann,Gesine Bug,Oliver G. Ottmann,Wolf-Karsten Hofmann,Brigitte Schlegelberger,Michael Heuser,Arnold Ganser +17 more
TL;DR: It is suggested that ASXL1 mutations are frequent molecular aberrations in MDS that predict an adverse prognostic outcome and Screening of patients for AS XL1 mutations might be useful for clinical risk stratification and treatment decisions in the future.
Journal ArticleDOI
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor
Katharina Wagner,Frederik Damm,Gudrun Göhring,Kerstin Görlich,Michael Heuser,Irina Schäfer,Oliver G. Ottmann,Michael Lübbert,Wolfgang Heit,Lothar Kanz,Günter Schlimok,Aruna Raghavachar,Walter Fiedler,Hartmut Kirchner,Wolfram Brugger,Manuela Zucknick,Brigitte Schlegelberger,Gerhard Heil,Arnold Ganser,Jürgen Krauter +19 more
TL;DR: IDH1 SNP rs11554137 but not IDH1 R132 mutations are associated with an inferior outcome in CN-AML, and the impact was most pronounced in the NPM1/FLT3 high-risk patients.
Journal ArticleDOI
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
Frederik Damm,Olivier Kosmider,Véronique Gelsi-Boyer,Véronique Gelsi-Boyer,Aline Renneville,Nadine Carbuccia,Nadine Carbuccia,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Véronique Della Valle,Véronique Della Valle,Véronique Della Valle,Lucile Couronné,Lucile Couronné,Lucile Couronné,Laurianne Scourzic,Laurianne Scourzic,Laurianne Scourzic,Virginie Chesnais,Agnès Guerci-Bresler,Bohrane Slama,Odile Beyne-Rauzy,Aline Schmidt-Tanguy,Aspasia Stamatoullas-Bastard,François Dreyfus,Thomas Prebet,Thomas Prebet,Stéphane de Botton,Norbert Vey,Norbert Vey,Michael A. Morgan,Nicholas C.P. Cross,Nicholas C.P. Cross,Claude Preudhomme,Daniel Birnbaum,Daniel Birnbaum,Olivier Bernard,Olivier Bernard,Olivier Bernard,Michaela Fontenay,Groupe Francophone des Myélodysplasies +40 more
TL;DR: It is demonstrated that splice gene mutations are among the most frequent molecular aberrations in myelodysplastic syndrome, define distinct clinical phenotypes, and show preferential associations with mutations targeting transcriptional regulation.